The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adjuvanted H5N1 vaccine induces early CD4+T cell response that predicts long-term persistence of protective antibody levels
Open accessAbstract
Immune responses to vaccination are tested in clinical trials. This process usually requires years especially when immune memory and persistence are analyzed. Markers able to quickly predict the immune response would be very useful, particularly when dealing with emerging diseases that require a rapid response, such as avian influenza. To address this question we vaccinated healthy adults at days 1, 22, and 202 with plain or MF59-adjuvanted H5N1 subunit vaccines and tested both cell-mediated and antibody responses up to day 382. Only the MF59-H5N1 vaccine induced high titers of neutralizing antibodies, a large pool of memory H5N1-specific B lymphocytes, and H5-CD4+T cells broadly reactive with drifted H5. The CD4+response was dominated by IL-2+IFN-γ−IL-13−T cells. Remarkably, a 3-fold increase in the frequency of virus-specific total CD4+T cells, measurable after 1 dose, accurately predicted the rise of neutralizing antibodies after booster immunization and their maintenance 6 months later. We suggest that CD4+T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
Strategies for mitigating an influenza pandemic
Ferguson, N. M., Cummings, D. A. T., Fraser, C., Cajka, J. C., Cooley, P. C., & Burke, D. S. (2006) · Nature · doi:10.1038/nature04795 · Cited by 2,187
T-cell quality in memory and protection: implications for vaccine design
Seder, R. A., Darrah, P. A., & Roederer, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2274 · Cited by 1,548
Antigen-specific interaction between T and B cells
Lanzavecchia, A. (1985) · Nature · doi:10.1038/314537a0 · Cited by 1,412
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W. B., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1592 · Cited by 1,378
Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Human TH1 and TH2 subsets: doubt no more
Romagnani, S. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90120-i · Cited by 1,089
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
Germinal-Center Organization and Cellular Dynamics
Allen, C. D. C., Okada, T., & Cyster, J. G. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.009 · Cited by 983
Wynn, T. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141142 · Cited by 958
Update on Avian Influenza A (H5N1) Virus Infection in Humans
(2008) · New England Journal of Medicine · doi:10.1056/nejmra0707279 · Cited by 860
ANTIGEN-SPECIFIC MEMORY B CELL DEVELOPMENT
McHeyzer-Williams, L. J., & McHeyzer-Williams, M. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115732 · Cited by 725
Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M., & Leroux-Roels, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61297-5 · Cited by 498
Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E., & Zambon, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05066-2 · Cited by 440
COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How
Castellino, F., & Germain, R. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115825 · Cited by 376
Self-citationInfluenza and the challenge for immunology
Doherty, P. C., Turner, S. J., Webby, R. G., & Thomas, P. G. (2006) · Nature Immunology · doi:10.1038/ni1343 · Cited by 356
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 285
Brown, D. M., Dilzer, A. M., Meents, D. L., & Swain, S. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.2888 · Cited by 282
Aversa, G., Punnonen, J., Cocks, B. G., de Waal Malefyt, R., Vega, F., Zurawski, S. M., Zurawski, G., & de Vries, J. E. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2213 · Cited by 221
Sasaki, S., Jaimes, M. C., Holmes, T. H., Dekker, C. L., Mahmood, K., Kemble, G. W., Arvin, A. M., & Greenberg, H. B. (2007) · Journal of Virology · doi:10.1128/jvi.01957-06 · Cited by 195
Confronting the avian influenza threat: vaccine development for a potential pandemic
Stephenson, I., Nicholson, K. G., Wood, J. M., Zambon, M. C., & Katz, J. M. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01105-3 · Cited by 173
Stephenson, I., Nicholson, K. G., Colegate, A., Podda, A., Wood, J., Ypma, E., & Zambon, M. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00632-1 · Cited by 166
Swain, S. L., Agrewala, J. N., Brown, D. M., Jelley‐Gibbs, D. M., Golech, S., Huston, G., Jones, S. C., Kamperschroer, C., Lee, W., McKinstry, K. K., et al. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00388.x · Cited by 163
Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Atmar, R. L., Keitel, W., Patel, S. M., Katz, J. M., She, D., Sahly, H. M. E., Pompey, J. M., Cate, T. R., & Couch, R. B. (2006) · Clinical Infectious Diseases · doi:10.1086/508174 · Cited by 148
Jung, T., Wijdenes, J., Neumann, C. R., de Vries, J. E., & Yssel, H. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260311 · Cited by 96
Eichelberger, M. C., Golding, H., Hess, M., Weir, J. P., Subbarao, K., Luke, C. J., Friede, M., & Wood, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.012 · Cited by 95
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Self-citationSimek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Calabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Metadata
- Authors
- Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C., Hilbert, A. K., Brauer, V., Banzhoff, A., Rappuoli, R., Del Giudice, G., & Castellino, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-03-10
- Volume
- 106
- Issue
- 10
- Pages
- 3877-3882
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1965145857
- Cited by
- 261
- References
- 27
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.